🇺🇸 FDA
Patent

US 9193790

Use of antagonists of the interaction between HIV GP120 and A4B7 integrin

granted A61KA61K2039/505A61K38/12

Quick answer

US patent 9193790 (Use of antagonists of the interaction between HIV GP120 and A4B7 integrin) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61K38/12, A61K39/3955, A61K45/06